Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain

Table 2 Improvements in GSQA scores from baseline to visit 6

GSQA Variables		ITT population (n = 114)
GSQA Variables		Trouble falling asleep	Need pain medication to sleep	Need sleep medication to sleep	Awakened by pain at night	Awakened by pain in the morning	Effect of pain on partner’s sleep
Baseline	n	114	114	114	114	114	86
	Median (range)	3.00 (0.00 to 10.00)	1.00 (0.00 to 10.00)	0.00 (0.00 to 10.00)	2.00 (0.00 to 10.00)	2.00 (0.00 to 10.00	1.00 (0.00 to 10.00)
	Mean (SD)	3.73 (3.18)	2.30 (2.96)	0.91 (2.13)	3.09 (3.19)	2.96 (3.41)	2.71 (3.42)
	Missing	0	0	0	0	0	28
Visit 6	n	93	93	93	93	93	80
	Median (range)	1.00 (0.00 to 10.00)	0.00 (0.00 to 10.00)	0.00 (0.00 to 10.00)	1.00 (0.00 to 10.00	2.00 (0.00 to 10.00	0.00 (0.00 to 10.00
	Mean (SD)	2.34 (2.85)	1.74 (2.86)	0.91 (2.13)	2.30 (2.89)	2.96 (3.41)	1.69 (2.60)
	Missing	21	21	21	21	21	34
^aChange	n	93	93	93	93	93	70
	^† p-value	<0.0001	0.001	0.578	0.004	<0.0001	0.007
	Median (range)	−1.00 (−10.00 to 5.00)	0.00 (−10.00 to 7.00)	0.00 (−10.00 to 10.00)	0.00 (−10.00 to 7.00)	−1.00 (−10.00 to 7.00)	0.00 (−10.00 to 5.00)
	Mean (SD)	−1.68 (3.15)	−0.86 (2.83)	−0.14 (2.85)	−1.04 (3.28)	−1.53 (3.27)	−1.09 (3.08)
	Missing	21	21	21	21	21	44

GSQA Global Sleep Quality Assessment Scale, ITT intent-to-treat, SD standard deviation
^aOnly patients with non-missing data at both visits 1 and 6 are included in the calculation for the change in scores from visit 1
^†Wilcoxon signed-rank test

ISSN: 1471-2474